Ana M. Gutierrez

Hospital General Universitario Dr Balmis Alicante, ISABIAL, CIBERehd
Alicante, VC, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 110 publications

Authors' reply: Therapeutic management and risk of colectomy in patients with acute severe ulcerative colitis and previous exposure to anti-tumor necrosis factor drugs: a comparative study of GETECCU.

Authors' reply: Therapeutic management and risk of colectomy in patients with acute severe ulcerative colitis and previous exposure to anti-tumor necrosis factor drugs: a comparative study of GETECCU.

Journal: Journal of Crohn's & colitis

Published: June 15, 2026

Impact of Prior Biologic Mechanism of Action on Anti-TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study.

Impact of Prior Biologic Mechanism of Action on Anti-TNF Effectiveness in Inflammatory Bowel Disease: An ENEIDA Registry Study.

Journal: Alimentary pharmacology & therapeutics

Published: March 14, 2026

Impact of celiac disease on the clinical course of inflammatory bowel disease: CEL_EII study by GETECCU.

Impact of celiac disease on the clinical course of inflammatory bowel disease: CEL_EII study by GETECCU.

Journal: Therapeutic advances in gastroenterology

Published: January 28, 2026

Predictors of Steroid Failure and Outcomes of Rescue Therapy in Severe ICI-Induced Colitis: A Multicenter Study from GETECCU.

Predictors of Steroid Failure and Outcomes of Rescue Therapy in Severe ICI-Induced Colitis: A Multicenter Study from GETECCU.

Journal: Digestive diseases and sciences

Published: January 05, 2026

The TECCU-Based Telemonitoring Platform for Inflammatory Bowel Disease Is Cost-Effective: A Multicenter GETECCU Trial.

The TECCU-Based Telemonitoring Platform for Inflammatory Bowel Disease Is Cost-Effective: A Multicenter GETECCU Trial.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: December 13, 2025

Addition of pulse corticosteroids to oral prednisone in moderately active ulcerative colitis: a randomized, multicentre, open-label study by GETECCU.

Addition of pulse corticosteroids to oral prednisone in moderately active ulcerative colitis: a randomized, multicentre, open-label study by GETECCU.

Journal: Journal of Crohn's & colitis

Published: November 19, 2025

GETECCU: a comprehensive national strategy for excellence in inflammatory bowel disease.

GETECCU: a comprehensive national strategy for excellence in inflammatory bowel disease.

Journal: Therapeutic advances in gastroenterology

Published: November 05, 2025

Hidradenitis suppurativa in patients with inflammatory bowel disease: a national multicenter study from the GETECCU-ENEIDA Registry.

Hidradenitis suppurativa in patients with inflammatory bowel disease: a national multicenter study from the GETECCU-ENEIDA Registry.

Journal: Therapeutic advances in gastroenterology

Published: October 17, 2025

Biological therapies for inflammatory pouch disorders: insights and outcomes from the RESERVO study of GETECCU.

Biological therapies for inflammatory pouch disorders: insights and outcomes from the RESERVO study of GETECCU.

Journal: Therapeutic advances in gastroenterology

Published: October 14, 2025

Comprehensive proteomic profile in newly diagnosed patients with inflammatory bowel disease: identification of potential biomarkers.

Comprehensive proteomic profile in newly diagnosed patients with inflammatory bowel disease: identification of potential biomarkers.

Journal: Journal of Crohn's & colitis

Published: October 09, 2025

Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-line Therapy in Anti-tumor Necrosis Factor-experienced Patients With Ulcerative Colitis.

Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-line Therapy in Anti-tumor Necrosis Factor-experienced Patients With Ulcerative Colitis.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: October 07, 2025

Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-Line Therapy in Anti-Tumor Necrosis Factor-Experienced Patients With Ulcerative Colitis.

Ustekinumab and Janus Kinase Inhibitors Outperform Vedolizumab as Second-Line Therapy in Anti-Tumor Necrosis Factor-Experienced Patients With Ulcerative Colitis.

Journal: Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association

Published: October 07, 2025

Showing 1-12 of 110

Last Updated: 09/26/2026